ERBB2 and neoplasm: More recently, Strassheimer et al. demonstrated that the combined treatment with human epidermal growth factor receptor 2 (HER2)-specific NK-92/5.28.z cells and anti-PD-1 blockade had a strong positive impact on tumor regression, long-term survival, and on cytotoxic lymphocyte infiltration [177].